Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday

by · The Cerbat Gem

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) is projected to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($1.42) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.47. On average, analysts expect Cadrenal Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cadrenal Therapeutics Price Performance

Shares of Cadrenal Therapeutics stock opened at $2.01 on Monday. The company has a 50-day moving average of $3.27 and a 200 day moving average of $5.21. The firm has a market cap of $6.87 million, a price-to-earnings ratio of -0.36 and a beta of 1.84. Cadrenal Therapeutics has a 1 year low of $1.86 and a 1 year high of $14.64.

Insider Activity

In other news, CEO Quang X. Pham sold 9,029 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.05, for a total transaction of $27,538.45. Following the sale, the chief executive officer owned 105,989 shares of the company’s stock, valued at $323,266.45. This trade represents a 7.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 97,500 shares of company stock worth $388,290. Company insiders own 26.09% of the company’s stock.

Institutional Investors Weigh In On Cadrenal Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics during the 3rd quarter valued at $103,000. DRW Securities LLC bought a new position in shares of Cadrenal Therapeutics during the 4th quarter valued at $171,000. Finally, Citadel Advisors LLC purchased a new position in shares of Cadrenal Therapeutics in the 3rd quarter worth $274,000. Institutional investors own 7.92% of the company’s stock.

Analyst Upgrades and Downgrades

CVKD has been the topic of a number of recent research reports. HC Wainwright cut their price objective on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $13.00.

Check Out Our Latest Research Report on Cadrenal Therapeutics

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Further Reading